Drugging the undruggable RAS: Mission Possible?
Open accessThe DOI matches its Crossref record; 231 of the 231 references it cites were found in a registry or an index.
Abstract
Despite more than three decades of intensive effort, no effective pharmacological inhibitors of the RAS oncoproteins have reached the clinic, prompting the widely held perception that RAS proteins are 'undruggable'. However, recent data from the laboratory and the clinic have renewed our hope for the development of RAS-inhibitory molecules. In this Review, we summarize the progress and the promise of five key approaches. Firstly, we focus on the prospects of using direct inhibitors of RAS. Secondly, we address the issue of whether blocking RAS membrane association is a viable approach. Thirdly, we assess the status of targeting RAS downstream effector signalling, which is arguably the most favourable current approach. Fourthly, we address whether the search for synthetic lethal interactors of mutant RAS still holds promise. Finally, RAS-mediated changes in cell metabolism have recently been described and we discuss whether these changes could be exploited for new therapeutic directions. We conclude with perspectives on how additional complexities, which are not yet fully understood, may affect each of these approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“KRAS has historically been considered ‘undruggable’ owing to a lack of pharmacologically targetable pockets within the mutant isoforms.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genetic analysis has shown that 98% of RAS mutations that cause cancer are concentrated in three residues: G12, G13, and Q61.”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A number of highly selective and potent inhibitors have been developed against kinases in the Ras signaling network particularly those in the MAPK and PI3K/mTOR pathways (9, 12).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For more than 40 years, KRAS mutation has been considered “undruggable” [16, 17].”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For many proteins known to be involved in driving diseases, such as KRAS in many cancers, conventional drug development strategies often aimed at developing inhibitors have failed [118, 119].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [119]
Experimental — accuracy not yet measured
17 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,890
Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation
Lunt, S. Y., & Vander Heiden, M. G. (2011) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154237 · Cited by 3,057
Research works printed but not linked: 1
- Kumar, M. S. et al. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 149, 642–655 (2012). · DOI · Paper page
Cited by
Items 1,001–1,007 of 1,007
Khawaja, H., Briggs, R., Latimer, C. H., Rassel, M., Griffin, D., Hanson, L., Bardelli, A., Di Nicolantonio, F., McDade, S. S., Scott, C. J., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0301 · Cited by 12
“org Mol Cancer Ther; 22(1) January 2023 143”
BackgroundInfluentialShin, W., Lee, S.-K., Hwang, J.-H., Park, J.-C., Cho, Y.-H., Ro, E. J., Song, Y., Seo, H. R., & Choi, K.-Y. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0102-5 · Cited by 10
Computational studies on the functional and structural impact of pathogenic mutations in enzymes
Dissanayake, U. C., Roy, A., Maghsoud, Y., Polara, S., Debnath, T., & Cisneros, G. A. (2025) · Protein Science · doi:10.1002/pro.70081 · Cited by 8
“…Radivoyevitch et al., 2011; Van Kuilenburg et al., 2004; Zinn et al., 1986), immune system disorders (Muul et al., 2003; Yoshihama et al., 2017), and various forms of cancers (Altman et al., 2016; Bryant et al., 2005; Church et al., 2013; Cox et al., 2014; Jafri et al., 2016; Parsons et al., 2008).”
Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges
Al-Hujaily, E. M., Al-Sowayan, B. S., Alyousef, Z., Uddin, S., & Alammari, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213696 · Cited by 6
“RAS activation induces the formation of an RAF-1/B-RAF heterodimer, which induces cell proliferation and differentiation through induction of the mitogen-activated protein kinase (MAPK) and the MAPK/ERK kinase (MEK) signaling pathway [90,91].”
BackgroundIsmail, M., Davies, G., Sproat, G., Monteverde, T., Tart, J., Acebrón-García-de-Eulate, M., Gohlke, A., Hancock, D., Adhikari, S., Stefanovic-Barrett, S., et al. (2024) · SLAS Discovery · doi:10.1016/j.slasd.2024.100197 · Cited by 6
Alawawdeh, A., Piantadosi, C., Townsend, A. R., Karapetis, C. S., Padbury, R., Roy, A. C., Moore, J., Maddern, G., Roder, D., Smith, A., et al. (2022) · Targeted Oncology · doi:10.1007/s11523-021-00856-9 · Cited by 5
“KRAS mutation is the predominant isoform observed in pancreatic, colon and lung carcinoma, while NRAS is more common with melanoma [5].”
BackgroundKano, Y. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135796
“Despite its biological importance, KRAS was long considered an “undruggable” target because of its high affinity for GTP/GDP and the lack of obvious druggable binding pockets [2,3].”
Metadata
- Authors
- Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Vanderbilt University (US)
- Dana-Farber Cancer Institute (US)
- National Cancer Institute (US)
- Corresponding author
- Der, Channing J.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-10-17
- Volume
- 13
- Issue
- 11
- Pages
- 828-851
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC4355017
- OpenAlex
- W2081990599
- Cited by
- 1,997
- References
- 231
- Citations by year
- 2026: 134 · 2025: 160 · 2024: 194 · 2023: 185 · 2022: 213 · 2021: 237 · 2020: 204 · 2019: 166 · 2018: 156 · 2017: 166 · 2016: 106 · 2015: 71 · 2014: 2
- FWCI
- 10.90
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (DP1OD006933, 5r01ca042978-30)
- U.S. Public Health Service (P50A095103-12)
- National Cancer Institute (P50CA127003, CA042978, R01CA175747, DP1CA174419, P50CA095103, CA175747, R01-CA042978, R21CA179193, RC2CA148375, CA179193, R01CA157490)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- oncogenic Ras, RAS inhibitors, undruggable targets, synthetic lethality, RAS-mutant cancers, anticancer drug discovery, Ras signaling
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Signal Transduction, Oncogene Proteins, ras Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.